Connect with the future of healthcare
EktaH, founded in 2021, originated from the Nutrition and Toxicology Department of the University of Bourgogne, backed by over 15 years of research in lipid metabolism. The company focuses on developing therapies that address the root causes of obesity, which impacts over 1 billion people worldwide. Instead of just treating the symptoms, EktaH aims to restore balance by targeting fat taste receptors to improve hormonal regulation, ultimately helping to correct unhealthy eating behaviours.
Premarket/clinical phase
4.200.000€
2028/2029
Biotechnology
18.89%
1.000€
Share this project on your website.
Copy and paste the following code into your content.
Obesity is a significant global health issue, linked to chronic conditions like type 2 diabetes and cardiovascular disease. It also places a heavy economic burden—costing the US alone $705 billion in 2019. Most current treatments, including drugs, surgery, and lifestyle changes, focus on managing symptoms and often have limited long-term success and side effects. In contrast, EktaH offers an innovative approach that targets the root cause: disordered eating behaviors.
Our lead candidate, NKS-3, is a small molecule that activates fat taste receptors, restoring natural satiety signals, controlling hunger, and promoting sustainable weight loss. Unlike GLP-1 agonists, which require frequent injections, NKS-3 is taken orally and has shown no side effects in clinical trials so far. It also reduced food intake by 40% in obese mice while preserving lean mass—an essential factor for long-term metabolic health. Additionally, the drug has shown safety and tolerability in early human trials, and EktaH is now moving into Phase Ib and II clinical trials to demonstrate its effectiveness in overweight or obese patients (BMI ≥ 27 kg/m²).
EktaH plans to bring NKS-3 to market by 2030. The company is in talks with major pharma partners, including Novo Nordisk and Eli Lilly, for a non-exclusive licensing agreement after completing Phase II trials. This partnership would include upfront payments of €180M, milestone payments, and sales royalties. The goal is to capture a 16% share of the obesity market, expected to exceed $150 billion by 2030.
EktaH is a promising alternative in the treatment of obesity, a growing problem at world level. EktaH has discovered NKS-3, a molecule that directly acts on the taste receptors of fats, improving the sensation of satiety of natural form. A difference in current treatments, which is centered in the gut and presents secondary effects, NKS-3 offers a more efficient solution, acting on the language to be able to achieve it without the effects of common adversaries.
With approved and pending patents, EktaH is advanced in clinical studies to validate the safety and effectiveness of NKS-3 in patients with overweight. The company has the potential to offer an effective and accessible solution to millions of people who need it.
With an experienced team and a disruptive force, EktaH is positioned to capture a significant part of the commercial market, a sector in constant growth and a great opportunity for investors.
Despite having one approved and one pending patent, EktaH may face hurdles in the regulatory environment, which could delay its market entry and limit its growth potential. In addition, it is critical for EktaH to generate robust clinical data to support the safety and efficacy of its agonists. Lack of convincing evidence could limit physicians' and patients' confidence in its products, hindering their adoption in the healthcare sector.
Already have an account? Please login here .
